Recommendations for the use of oral treprostinil in clinical practice: A delphi consensus project pulmonary circulation

Franck F. Rahaghi, Jeremy P. Feldman, Roblee P Allen, Victor Tapson, Zeenat Safdar, Vijay P. Balasubramanian, Shelley Shapiro, Michael A. Mathier, Jean M. Elwing, Murali M. Chakinala, R. James White

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Oral treprostinil was recently labeled for treatment of pulmonary arterial hypertension. Similar to the period immediately after parenteral treprostinil was approved, there is a significant knowledge gap for practicing physicians who might prescribe oral treprostinil. Despite its oral route of delivery, use of the drug is challenging because of the requirement for careful titration and management of drug-related adverse effects. We aimed to create a consensus document combining available evidence with expert opinion to provide guidance for use of oral treprostinil. Following a methodology commonly used in business and social sciences (the ‘Delphi Process’), two investigators from the oral treprostinil (Freedom) studies created a series of statements based on available evidence and the package insert. The set of ‘best practice’ statements was circulated to nine other Freedom trial investigators. Their comments were incorporated into the document as new line items for further vote and comment. The subsequent document was put to vote line by line (scale of -5 to +5) and a final statement was drafted. Consensus recommendations include initial therapy with 0.125 mg for treatment nay¨ve patients, three times daily dosing, aggressive use of antidiarrheal medication, and a strong preference for use of the drug in combination with other approved PAH therapies. This process was particularly valuable in providing guidance for the management of adverse events (where essentially no data is available). The Delphi process was useful to codify investigator experience and subsequently develop investigator consensus about practical issues for physicians who may wish to prescribe oral treprostinil.

Original languageEnglish (US)
Pages (from-to)167-174
Number of pages8
JournalPulmonary Circulation
Volume7
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Pulmonary Circulation
Consensus
Research Personnel
Product Labeling
Antidiarrheals
Physicians
Social Sciences
Expert Testimony
Drug Combinations
Therapeutics
Practice Guidelines
Pulmonary Hypertension
Pharmaceutical Preparations
treprostinil

Keywords

  • Drug side effects
  • Oral treprostinil
  • Pulmonary arterial hypertension
  • Pulmonary delphi studies

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Rahaghi, F. F., Feldman, J. P., Allen, R. P., Tapson, V., Safdar, Z., Balasubramanian, V. P., ... White, R. J. (2017). Recommendations for the use of oral treprostinil in clinical practice: A delphi consensus project pulmonary circulation. Pulmonary Circulation, 7(1), 167-174. https://doi.org/10.1086/690109

Recommendations for the use of oral treprostinil in clinical practice : A delphi consensus project pulmonary circulation. / Rahaghi, Franck F.; Feldman, Jeremy P.; Allen, Roblee P; Tapson, Victor; Safdar, Zeenat; Balasubramanian, Vijay P.; Shapiro, Shelley; Mathier, Michael A.; Elwing, Jean M.; Chakinala, Murali M.; White, R. James.

In: Pulmonary Circulation, Vol. 7, No. 1, 01.01.2017, p. 167-174.

Research output: Contribution to journalArticle

Rahaghi, FF, Feldman, JP, Allen, RP, Tapson, V, Safdar, Z, Balasubramanian, VP, Shapiro, S, Mathier, MA, Elwing, JM, Chakinala, MM & White, RJ 2017, 'Recommendations for the use of oral treprostinil in clinical practice: A delphi consensus project pulmonary circulation', Pulmonary Circulation, vol. 7, no. 1, pp. 167-174. https://doi.org/10.1086/690109
Rahaghi, Franck F. ; Feldman, Jeremy P. ; Allen, Roblee P ; Tapson, Victor ; Safdar, Zeenat ; Balasubramanian, Vijay P. ; Shapiro, Shelley ; Mathier, Michael A. ; Elwing, Jean M. ; Chakinala, Murali M. ; White, R. James. / Recommendations for the use of oral treprostinil in clinical practice : A delphi consensus project pulmonary circulation. In: Pulmonary Circulation. 2017 ; Vol. 7, No. 1. pp. 167-174.
@article{d971af7f1d434bc0afa25d66a9e7def4,
title = "Recommendations for the use of oral treprostinil in clinical practice: A delphi consensus project pulmonary circulation",
abstract = "Oral treprostinil was recently labeled for treatment of pulmonary arterial hypertension. Similar to the period immediately after parenteral treprostinil was approved, there is a significant knowledge gap for practicing physicians who might prescribe oral treprostinil. Despite its oral route of delivery, use of the drug is challenging because of the requirement for careful titration and management of drug-related adverse effects. We aimed to create a consensus document combining available evidence with expert opinion to provide guidance for use of oral treprostinil. Following a methodology commonly used in business and social sciences (the ‘Delphi Process’), two investigators from the oral treprostinil (Freedom) studies created a series of statements based on available evidence and the package insert. The set of ‘best practice’ statements was circulated to nine other Freedom trial investigators. Their comments were incorporated into the document as new line items for further vote and comment. The subsequent document was put to vote line by line (scale of -5 to +5) and a final statement was drafted. Consensus recommendations include initial therapy with 0.125 mg for treatment nay¨ve patients, three times daily dosing, aggressive use of antidiarrheal medication, and a strong preference for use of the drug in combination with other approved PAH therapies. This process was particularly valuable in providing guidance for the management of adverse events (where essentially no data is available). The Delphi process was useful to codify investigator experience and subsequently develop investigator consensus about practical issues for physicians who may wish to prescribe oral treprostinil.",
keywords = "Drug side effects, Oral treprostinil, Pulmonary arterial hypertension, Pulmonary delphi studies",
author = "Rahaghi, {Franck F.} and Feldman, {Jeremy P.} and Allen, {Roblee P} and Victor Tapson and Zeenat Safdar and Balasubramanian, {Vijay P.} and Shelley Shapiro and Mathier, {Michael A.} and Elwing, {Jean M.} and Chakinala, {Murali M.} and White, {R. James}",
year = "2017",
month = "1",
day = "1",
doi = "10.1086/690109",
language = "English (US)",
volume = "7",
pages = "167--174",
journal = "Pulmonary Circulation",
issn = "2045-8932",
publisher = "University of Chicago Press",
number = "1",

}

TY - JOUR

T1 - Recommendations for the use of oral treprostinil in clinical practice

T2 - A delphi consensus project pulmonary circulation

AU - Rahaghi, Franck F.

AU - Feldman, Jeremy P.

AU - Allen, Roblee P

AU - Tapson, Victor

AU - Safdar, Zeenat

AU - Balasubramanian, Vijay P.

AU - Shapiro, Shelley

AU - Mathier, Michael A.

AU - Elwing, Jean M.

AU - Chakinala, Murali M.

AU - White, R. James

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Oral treprostinil was recently labeled for treatment of pulmonary arterial hypertension. Similar to the period immediately after parenteral treprostinil was approved, there is a significant knowledge gap for practicing physicians who might prescribe oral treprostinil. Despite its oral route of delivery, use of the drug is challenging because of the requirement for careful titration and management of drug-related adverse effects. We aimed to create a consensus document combining available evidence with expert opinion to provide guidance for use of oral treprostinil. Following a methodology commonly used in business and social sciences (the ‘Delphi Process’), two investigators from the oral treprostinil (Freedom) studies created a series of statements based on available evidence and the package insert. The set of ‘best practice’ statements was circulated to nine other Freedom trial investigators. Their comments were incorporated into the document as new line items for further vote and comment. The subsequent document was put to vote line by line (scale of -5 to +5) and a final statement was drafted. Consensus recommendations include initial therapy with 0.125 mg for treatment nay¨ve patients, three times daily dosing, aggressive use of antidiarrheal medication, and a strong preference for use of the drug in combination with other approved PAH therapies. This process was particularly valuable in providing guidance for the management of adverse events (where essentially no data is available). The Delphi process was useful to codify investigator experience and subsequently develop investigator consensus about practical issues for physicians who may wish to prescribe oral treprostinil.

AB - Oral treprostinil was recently labeled for treatment of pulmonary arterial hypertension. Similar to the period immediately after parenteral treprostinil was approved, there is a significant knowledge gap for practicing physicians who might prescribe oral treprostinil. Despite its oral route of delivery, use of the drug is challenging because of the requirement for careful titration and management of drug-related adverse effects. We aimed to create a consensus document combining available evidence with expert opinion to provide guidance for use of oral treprostinil. Following a methodology commonly used in business and social sciences (the ‘Delphi Process’), two investigators from the oral treprostinil (Freedom) studies created a series of statements based on available evidence and the package insert. The set of ‘best practice’ statements was circulated to nine other Freedom trial investigators. Their comments were incorporated into the document as new line items for further vote and comment. The subsequent document was put to vote line by line (scale of -5 to +5) and a final statement was drafted. Consensus recommendations include initial therapy with 0.125 mg for treatment nay¨ve patients, three times daily dosing, aggressive use of antidiarrheal medication, and a strong preference for use of the drug in combination with other approved PAH therapies. This process was particularly valuable in providing guidance for the management of adverse events (where essentially no data is available). The Delphi process was useful to codify investigator experience and subsequently develop investigator consensus about practical issues for physicians who may wish to prescribe oral treprostinil.

KW - Drug side effects

KW - Oral treprostinil

KW - Pulmonary arterial hypertension

KW - Pulmonary delphi studies

UR - http://www.scopus.com/inward/record.url?scp=85032393786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032393786&partnerID=8YFLogxK

U2 - 10.1086/690109

DO - 10.1086/690109

M3 - Article

AN - SCOPUS:85032393786

VL - 7

SP - 167

EP - 174

JO - Pulmonary Circulation

JF - Pulmonary Circulation

SN - 2045-8932

IS - 1

ER -